CYXN China Yongxin Pharmaceuticals Inc. featured news, full reports, and detailed charts
China Yongxin Pharmaceuticals Inc. (CYXN/CYXN.OB) Wrap Up:
China Yongxin Pharmaceuticals, Inc. engages in the wholesale distribution of pharmaceutical products, medical products and equipment, herbal and nutritional supplements, and cosmetics to hospitals, clinics, and retail pharmacies primarily in the People’s Republic of China. It also operates drugstores that offer 8,000 different types of products, including its proprietary brand of ginseng-based products, as well as an assortment of other merchandise comprising traditional Chinese medicines, health and natural products, skin care products, and cosmetics. The company involves in the cultivation, processing, manufacture, and distribution of ginseng electuary, pellets, and liquid extracts that ar...642 Employees
Founded in 1993
China Yongxin Pharmaceuticals Inc. (CYXN:OTC Bulletin Board Market)
LAST $0.49 USD
CHANGE TODAY -0.01 -2.00%
VOLUME 253.5K
As of 3:58 PM 11/19/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of China Yongxin Pharmaceuticals Inc. (CYXN)
|
OPEN
$0.50
|
PREVIOUS CLOSE
$0.50
|
|
|
DAY HIGH
$0.53
|
DAY LOW
$0.45
|
|
|
52 WEEK HIGH
10/19/09 - $0.80
|
52 WEEK LOW
11/26/08 - $0.05
|
|
|
MARKET CAP
17.4M
|
AVERAGE VOLUME 3 mo
68.6K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
35.4M
|
|
|
CYXN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
CYXN Top Compensated Officers
Mr. Yongxin Liu
Chairman and Chief Executive Officer
Age: 41
Total Annual Compensation: $88.0K
Mr. Yongkui Liu
Chief Financial Officer, Principal Accounting...
Age: 39
Total Annual Compensation: $70.4K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for China Yongxin Pharmaceuticals Inc. (CYXN)
China Yongxin Pharmaceuticals, Inc. Announces Board Changes
11/12/2009
Effective November 8, 2009, Mr. Umesh Patel tendered his resignation as a director from the board of directors of China Yongxin Pharmaceuticals Inc. Effective November 8, 2009, Mr. Harry Zhang was appointed as a director of the Company. From June 2007 to the present, Mr. Zhang serves as the Chief Financial Officer and Vice President of an investment company. From March 2004 to August 2006, Mr. Zhang served as the Chief Financial Officer of AXM Pharma, Inc.
China Yongxin Pharmaceuticals Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2009
10/14/2009
China Yongxin Pharmaceuticals Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2009. Revenues for the second quarter of 2009 were essentially flat at approximately $14.6 million compared to $14.58 million in the second quarter of 2008, with a marginal increase due to an increase in revenue from its retail drug stores offset by a decrease in volume from its pharmaceutical wholesale business. Operating income totaled approximately $1.2 million, a 9.0% decrease from the $1.3 million reported for the second quarter of 2008. Net income was approximately $1.0 million, a 44.8% increase from the $0.7 million reported during the second quarter of 2008. The increase was primarily related to the absence of a $0.2 million interest expense which occurred during the second quarter of 2008. Diluted earnings per share were $0.03 compared to $0.02 for the second quarter of 2009 and 2008 respectively. Operating income before income tax and non controlling interest was $1.86 million compared to $1.78 million a year ago. Net income before non controlling interest was $1.34 million compared to $1.2 million a year ago. Net comprehensive income was $1 million compared to $1.01 million a year ago. For the six months, revenues decreased approximately 19.4% to $23.8 million compared to $29.57 million the same period in 2008. Income from operations was $1.8 million, representing a decrease of 27.6% over $2.55 million in the first six months of 2008. Net income decreased marginally to $1.46 million compared to $1.49 million in the same period in 2008. Diluted earnings per share were $0.05 compared to $0.05 for the first six months of fiscal 2009 and 2008 respectively. Operating income before income tax and non controlling interest was $2.6 million compared to $3.1 million a year ago. Net income before non controlling interest was $1.895 million compared to $2.2 million a year ago. Net comprehensive income was $1.4 million compared to $2.32 million a year ago. Net cash provided by operating activities was $1 million compared to $1.96 million a year ago. Additions to construction in progress was $275,529.
China Yongxin Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2008
04/23/2009
China Yongxin Pharmaceuticals Inc. reported earnings results for the fourth quarter and year ended December 31, 2008. Yongxin announced record revenue for its fourth quarter of $14.1 million, representing a 28.6% increase from $11 million recorded in the fourth quarter of fiscal 2007. The revenue growth was driven by increased sales from both its wholesale distribution and retail business segment. Net income for the quarter was $0.9 million, down from net income of $1.3 million in the same period a year ago. Diluted earnings per share were $0.03 for the fourth quarter of 2008, compared to diluted earnings per share of $0.06 in the fourth quarter of 2007, utilizing 31.2 million shares and 21 million shares respectively. For the fiscal year ended December 31, 2008, Yongxin announced record revenue of $59.1 million, a 23.5% increase versus $47.9 million reported for 2007. For fiscal 2008, net income was approximately $4.1 million, an increase of 13.7% from $3.6 million recorded for fiscal 2007. Fully diluted earnings per share for 2008 and 2007 were $0.13 and $0.16 respectively, based on 31.2 million and 22.4 million shares for 2008 and 2007, respectively. For the fiscal year of 2008, the Company generated $5.9 million in cash from operations versus net cash used in operations of $1.8 million for the same period in 2007. The increase in cash flow was primarily attributable to an increase in net income and decrease in accounts receivable, advances to suppliers and inventory, while partially offset by a decrease in accounts payable.
CYXN Competitors
| Company | Last | Change |
| China Nepstar Chain Drugstore Ltd | $6.99 USD | -0.01 |
| Guangzhou Pharmaceutical Co Ltd | ¥13.26 CNY | +0.54 |
| Liaoning Cheng Da Co Ltd | ¥39.05 CNY | -0.55 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CYXN | Industry Range |
| Price/Earnings | 3.9x |
|
| Price/Sales | 0.3x |
|
| Price/Book | 1.0x |
|
| Price/Cash Flow | 4.0x |
|
| TEV/Sales | 0.1x |
|
|
CYXN |
||
|
CYXN transactions
| Type Date |
Target |
|
Private Placement
September 25, 2009 |
-- |
More Recent News About China Yongxin Pharmaceuticals Inc.
More news for CYXN
CHINA YONGXIN PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers. Resignation of Director Effective November 8, 2009, Mr. Umesh Patel tendered his resignation as a director from the board of directors of China Yongxin Pharmaceuticals Inc. (the "Company"). There were no disagreements between Mr. Patel and any officer or director of the Company. The Company provided a copy of the disclosures it is making in response to this Item 5.02 to Mr. Patel and informed him that he may furnish the Company with a letter stating whether he agrees or disagrees with the disclosures made in response to this Item 5.02, and that if he disagrees, then the Company requests that he provides the respects in which he does not agree with the disclosures. The Company will undertake to file any letter received from Mr. Patel, if any, as an exhibit to an amendment to this current report on Form 8-K within two business days after receipt. Appointment of New Director Effective November 8, 2009, Mr. Harry Zhang was appointed as a director of the Company. From June 2007 to the present, Mr. Zhang serves as the Chief Financial Officer and Vice President of an investment company. From March 2004 to August 2006, Mr. Zhang served as the Chief Financial Officer of AXM Pharma, Inc. Mr. Zhang worked as an auditor at Deloitte Touche Tohmatsu between May 1995 to March 2004. Mr. Zhang worked at the Beijing Municipal Audit Bureau from 1988 to 1995. Mr. Zhang earned his Bachelor's degree from Nanjing Agricultural University in 1988 and received his Master of Business Administration degree from University of Northern Virginia in June 2007. Mr. Zhang is also a CPA of Association China Institute. Mr. Zhang does not hold any other directorship in any other reporting company. Mr. Zhang has not been appointed to any committee of the board of directors. There are no family relationships among the Company's directors, executive...Click here to read the whole Article (external link)
CHINA YONGXIN PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial State
Show all filings for CHINA YONGXIN PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for CHINA YONGXIN PHARMACEUTICALS INC. 20-Oct-2009Results of Operations and Financial Condition, Financial State Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All ...Click here to read the whole Article (external link)
China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results
CHANGCHUN, China and LOS ANGELES, Oct. 14 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China Yongxin Pharmaceuticals" or "the Company"), a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced its unaudited financial results for the second quarter of 2009 which ended June 30, 2009. Revenues for the second quarter of 2009 were essentially flat at approximately $14.6 million compared to the second quarter of 2008, with a marginal increase due to an increase in revenue from its retail drug stores offset by a decrease in volume from its pharmaceutical wholesale business. Revenues from retail drug stores were $6.0 million, compared to $5.8 million for the same period in 2008, which included a 10.9% increase for existing same store sales. A broader product portfolio, in addition to increased marketing activities, contributed to the growth. During the quarter, the Company launched one new chain drug store in Tianjin."We believe our business during the first half of 2009 was impacted by customers waiting for specifics on the new healthcare reform plan. On August 18 the Chinese government issued China's Essential Drug List (EDL) which included 307 commonly used pharmaceuticals. These will be subsidized by the government to provide easier access to all citizens. China Yongxin distributes 295 products included on this list and we believe our Company will benefit from the government's efforts to boost domestic spending, in addition to the new healthcare reform which is gaining momentum," commented Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin. "We have added 12 high margin pharmaceutical products with exclusive distribution rights in Jilin province in the first half of 2009 and we expect this to drive market share gains and growth during the b...Click here to read the whole Article (external link)
CHINA YONGXIN PHARMACEUTICALS INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements a
Show all filings for CHINA YONGXIN PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for CHINA YONGXIN PHARMACEUTICALS INC. 30-Sep-2009Unregistered Sale of Equity Securities, Financial Statements a Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All i...Click here to read the whole Article (external link)
CHINA YONGXIN PHARMACEUTICALS INC. Financials
PERIOD ENDING30-Jun-0931-Mar-0931-Dec-0830-Sep-08Total Revenue14,639 9,185 14,098 15,451 Cost of Revenue11,920 6,954 10,625 12,413 Gross Profit2,719 2,231 3,474 3,039 Operating ExpensesResearch Development - - - - Selling General and Administrative1,530 1,575 2,045 1,228 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss1,188 656 1,429 1,811 Income from Continuing OperationsTotal Other Income/Expenses Net712 70 (902)641 Earnings Before Interest And Taxes1,900 726 527 2,452 Interest Expense - - (274)56 Income Before Tax1,900 726 801 2,396 Income Tax Expense526 205 (478)547 Minority Interest(430) - (356)(192)Net Income From Continuing Ops944 521 923 1,657 Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - ...Click here to read the whole Article (external link)
CHINA YONGXIN PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion relates to a discussion of the financial condition and results of operations of China Yongxin Pharmaceuticals Inc. (formerly Digital Learning Management Corporation and Nutradyne Group, Inc.) (the "Company") and its subsidiaries. This management's discussion and analysis of financial condition and results of operations for the three month and six month periods ending June 30, 2009 and June 30, 2008 should be read in conjunction with its financial statements and the related notes, and the other financial information included in this report. Forward-Looking Statements The following discussion should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this report. This report contains forward-looking statements. The words "anticipated," "believe," "expect, "plan," "intend," "seek," "estimate," "project," "could," "may" and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect our management's current views with respect to future events and financial performance and involve risks and uncertainties, including, without limitation, general economic and business conditions, changes in foreign, political, social, and economic conditions, regulatory initiatives and compliance with governmental regulations, the ability to achieve further market penetration and additional customers, and various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those an...Click here to read the whole Article (external link)
Five Top Chinese Pharma Plays
#popupbox { position: relative; } #share_links_popup { top: 12px; *top: 62px; /*ie*/ left: -120px; } #share_links_popup { text-transform:none; font-family:sans-serif; font-weight:normal; text-align:left; border:1px solid #cdcdcd; width:125px !important; padding:3px; display:none; z-index:100; background-color:white; position:absolute; } .sharelink_icon { background-image:url(/css/images/article_tools_icons.gif); background-repeat:no-repeat; border:0px solid gray; height:16px !important; padding-left:24px; padding-right:24px; font-size:8pt; font-family:Trebuchet MS; text-decoration:none; letter-spacing:0.01em; display:block; margin-top:4px !important; margin-bottom:4px; color:#000; width:90px !important; } #share_close_box { margin-right:2px; margin-top:2px; background-position:0 -184px ; width:16px; height:11px; font-family:sans-serif; font-weight:bold; text-decoration:none; float:right; } #share_close_box a { text-decoration:none; color:#cc0000; } #share_close_box a:hover { color:red; } #share_links { margin-top:4px; margin-left:0px; } #share_header { width:100%; /*background-color:#dedede; */ font-family:sans-serif; font-size:9pt; padding:4px; } ...Click here to read the whole Article (external link)
CHINA YONGXIN PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion relates to a discussion of the financial condition and results of operations of China Yongxin Pharmaceuticals Inc. (formerly Digital Learning Management Corporation and Nutradyne Group, Inc.) (the "Company") and its subsidiaries. This management's discussion and analysis of financial condition and results of operations for three month periods ending March 31, 2009 and March 31, 2008 should be read in conjunction with its financial statements and the related notes, and the other financial information included in this report. Forward-Looking Statements The following discussion should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this report. This report contains forward-looking statements. The words "anticipated," "believe," "expect, "plan," "intend," "seek," "estimate," "project," "could," "may" and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect our management's current views with respect to future events and financial performance and involve risks and uncertainties, including, without limitation, general economic and business conditions, changes in foreign, political, social, and economic conditions, regulatory initiatives and compliance with governmental regulations, the ability to achieve further market penetration and additional customers, and various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, belie...Click here to read the whole Article (external link)
CHINA YONGXIN PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS The following discussion should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. This report contains forward-looking statements. The words "anticipated," "believe," "expect," "plan," "intend," "seek," "estimate," "project," "could," "may," and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect our management's current views with respect to future events and financial performance and involve risks and uncertainties, including, without limitation, general economic and business conditions, changes in foreign, political, social, and economic conditions, regulatory initiatives and compliance with government regulations, the ability to achieve further market penetration and additional customer, and various other matters, any of which are beyond our control. Should one or more of these risks and uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated or otherwise indicated. Consequently, all of the forward-looking statements made in this report are qualified by these cautionary statements and there can be no assurance of the actual results or developments. CRITICAL ACCOUNTING POLICIES AND ESTIMATES The SEC defines critical accounting policies as those that are, in management's view, most important to the portrayal of our financial condition and results of operations and those that require significant judgments and estimates. The preparation of these consolidated financial statements requires our management to make estimates and assumptions that affe...Click here to read the whole Article (external link)
China Yongxin Pharmaceuticals, Inc. Establishes Retailing Chain Management Head Office to Uniformly Manage Its Growing Base of Chain Drugstores
CHANGCHUN, CHINA and LOS ANGELES, CA--(MARKET WIRE)--Dec 2, 2008 -- China Yongxin Pharmaceuticals, Inc. ("China Yongxin Pharmaceuticals" or "the Company") (OTC BB:CYXN.OB - News), a leading distributor and retailer of pharmaceuticals in Northeastern China, announced today that it has recently established a Retailing Chain Management Head Office to uniformly manage its growing base of chain drugstores. "We established the Retailing Chain Management Head Office to further the implementation of our 5-year strategic development plan for the retailing chain business of China Yongxin," stated Mr. Yongxin Liu, Chairman and CEO of China Yongxin Pharmaceuticals, Inc. "This facility will allow us to plan for the expansion of the retailing chain through all levels, to integrate our resources and methodically execute on rolling out new stores. Concurrently, it will allow us to set up a standardized medicine retailing chain operation system, to construct a scalable operation that adopts international standards, and enjoys competition in the market. Additionally, the Head Office helps to create the China Yongxin retailing chain brand image with a unique chain operations pattern. So, in effect, this facility will help us to enhance our competitive advantage."He added, "The establishment of the China Yongxin Retailing Chain Management Head Office signals that China Yongxin's retail chain business has entered into a new phase of growth. The implementation of a uniform 'VI' system, a standardized operations handbook, a uniform business manag...Click here to read the whole Article (external link)
Would you like to leave a comment about China Yongxin Pharmaceuticals Inc. CYXN/CYXN.OB
Find out what social network information about China Yongxin Pharmaceuticals Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides China Yongxin Pharmaceuticals Inc. there is more great information available at Realpennies.com